Multi-omics Characterization of Pancreatic Neuroendocrine Tumors and Carcinomas

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

300 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-12-01

Study Completion Date

2022-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this work, the investigators count through the integrated multi-omics analysis to identify different tumor subgroups in pancreatic neuroendocrine tumors and carcinomas regardless of their grade and stage. To achieve this, they will resort to the use of next-generation sequencing approaches (RNAseq, then use of MCP Counter for the absolute quantification of the eight populations of immune cells in the tumor microenvironment), alterations in epigenetics with study of the methylome by MeDIP, ChIPseq, telomere (ALT) study, as well as correlation with peripheral blood neutrophil to lymphocyte ratio and immunohistochemistry data such as Ki67, p53, Rb, DAXX, ATRX, PDL1, immune cell labeling. This will be done on frozen or paraffin material. This work will provide a more complete biological picture of pancreatic neuroendocrine tumors and carcinomas.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of Survival Prognostic Factors for Patients With Exocrine Pancreatic Cancer Resectable or Potentially Resectable

NCT02818907

Pancreatic Cancer

COMPLETED NA

Role of Perfusion CT in Pancreatic Cancer

NCT01703650

Adenocarcinoma, Pancreas Neuroendocrine Carcinoma of Pancreas

UNKNOWN

Diagnostic Strategies, Risk Assessment and Progression of Pancreatic Cysts

NCT04473794

Pancreatic Neoplasms Pancreas Cancer

RECRUITING

Detection of Circulating Tumor Cells for the Diagnostic of Pancreatic Adenocarcinoma.

NCT02072616

Circulating Tumor Cells Pancreatic Adenocarcinoma Circulating Tumor DNA (KRAS) +1 more

UNKNOWN PHASE3

Diagnostic Accuracy of Circulating Tumor Cells (CTCs) and Onco-exosome Quantification in the Diagnosis of Pancreatic Cancer - PANC-CTC

NCT03032913

Pancreatic Ductal Adenocarcinoma (PDAC)

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer of Pancreas

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patient (≥18 years old)
* Subject with histologically confirmed tumor or neuroendocrine carcinoma of the pancreas
* Subject with tumors or neuroendocrine carcinoma of the pancreas regardless of the stage of the disease
* Supported at the University Hospitals of Strasbourg between 01/01/2008 and 01/09/2019
* Near therapeutic blood count available (less than 6 months)
* Availability of frozen and/or paraffin tumor material
* Patients who have already given their consent for their biological resources to be kept at the CRB or in the anatomopathology department of the HUS, and subsequently reused, as well as the anonymous data associated with them, for scientific research purposes.

* Impossibility of giving informed information to the subject
* Patient under judicial protection En savoir plus sur ce texte sourceVous devez indiquer le texte source pour obtenir des informations supplémentaires Envoyer des commentaires Panneaux latéraux